NanoMed closes initial financing
Michigan, USA-headquartered NanoMed Pharmaceuticals, a drug-delivery company developing nanoparticle-based therapeutic and diagnostic products to treat or detect disease, has closed on its first round of venture financing. The investment was led by the SWMF Life Science Venture Fund, a $50.0 million private equity fund investing exclusively in promising life science companies having a presence in the Kalamazoo Region.
NanoMed chief executive Stephen Benoit said: "we are extremely pleased to have secured the necessary funding that will enable us to continue our development of nanoparticle-based drugs that we hope will lead to improved outcomes for patients undergoing chemotherapy for AML and breast cancer."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze